Avotermin
Also known as: Avotermin, Juvista, recombinant human TGF-beta3, rhTGF-β3, TGF‑β3
Source Avotermin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Avotermin (recombinant human TGF‑β3) is a topical formulation investigated for scar reduction after surgery; Phase III trials failed to meet primary endpoints and development was discontinued, so it remains investigational and not approved.
Mechanism of Action
Recombinant human TGF-β3 modulates wound healing by regulating fibroblast activity, collagen synthesis, and extracellular matrix remodeling, leading to reduced scar formation.
Routes of Administration
Goals & Uses
- Scar preventionDermatology / Wound HealingModerate
- improved wound healingTherapeuticLow
- Reduction of hypertrophic scarringDermatologyLow
- scar reductionCosmeticModerate
- Improved cosmetic wound outcomesAesthetic MedicineLow
Contraindications
- Active infection at wound siteInfectionModerate
- History of keloid or abnormal scarring disordersDermatologyModerate
- Known hypersensitivity to TGF-β3 or excipientsAllergyHigh
- hypersensitivity to TGF‑β3AllergyHigh
Adverse Effects
- Injection site painLocalCommonPain at the injection site
- PruritusDermatologicCommonItching
- Contact dermatitisDermatologicalUncommon
- Injection site edemaLocal ReactionCommon
- Hypersensitivity reactionImmunologicRare
- erythemaLocalCommon
- Injection site erythemaLocalCommonRedness at the injection site
Drug Interactions
- NSAIDsLowMay increase renal risk in susceptible patients
- CorticosteroidsModerate
- other topical wound healing agentsLow
Population Constraints
- Patients with active malignancyOncologyRelative
- Pediatric patientsAgeRelative
- Immunocompromised patientsImmunologicRelative
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionInvestigationalClinical trial application submitted; no marketing authorization.
- United StatesInvestigationalInvestigational New Drug (IND) status; not approved.
- United KingdomInvestigationalUnder clinical investigation; not approved.
Not approved by FDA, EMA, or MHRA; classified as an investigational new drug.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Avotermin?
Avotermin (recombinant human TGF‑β3) is a topical formulation investigated for scar reduction after surgery; Phase III trials failed to meet primary endpoints and development was discontinued, so it remains investigational and not approved.
What is Avotermin used for?
Avotermin is educationally associated with: Scar prevention, improved wound healing, Reduction of hypertrophic scarring, scar reduction, Improved cosmetic wound outcomes. Educational only — not medical advice.
How is Avotermin administered?
Recorded routes of administration: Intradermal, Topical.
What are the potential side effects of Avotermin?
Reported adverse effects include: Injection site pain, Pruritus, Contact dermatitis, Injection site edema, Hypersensitivity reaction, erythema, Injection site erythema. This list is not exhaustive — consult a qualified clinician.
Who should avoid Avotermin?
Recorded contraindications: Active infection at wound site, History of keloid or abnormal scarring disorders, Known hypersensitivity to TGF-β3 or excipients, hypersensitivity to TGF‑β3. Consult a qualified clinician before use.